Lipid nano-bubble combined with ultrasound for anti-keloids therapy

References

• Baka E, Comer J, Takács-Novák K. (2008). Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J Pharm Biomed Anal 46:335–41
   PubMed Web of Science ®Google Scholar
• Di Paolo D, Pastorino F, Zuccari G, et al. (2013). Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. J Control Release 170:445–51
   PubMed Web of Science ®Google Scholar
• Fan Z, Liu H, Mayer M, Deng CX. (2012). Spatiotemporally controlled single cell sonoporation. Proc Natl Acad Sci U S A 109:16486–91
   PubMed Web of Science ®Google Scholar
• Gauglitz GG, Korting HC, Pavicic T, et al. (2011). Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 17:113–25
   PubMed Web of Science ®Google Scholar
• Huang C, Murphy GF, Akaishi S. (2013). Keloids and hypertrophic scars: update and future directions. Plast Reconstr Surg Glob Open 1:e25
   PubMedGoogle Scholar
• Juffermans LJ, Meijering DB, van. Wamel A, et al. (2009). Ultrasound and microbubble-targeted delivery of therapeutic compounds: ICIN Report Project 49: drug and gene delivery through ultrasound and microbubbles. Neth Heart J 17:82–6
   PubMedGoogle Scholar
• Kang J, Wu X, Wang Z, et al. (2010). Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. J Ultrasound Med 29:61–70
   PubMed Web of Science ®Google Scholar
• Liang HD, Tang J, Halliwell M. (2010). Sonoporation, drug delivery, and gene therapy. Proc Inst Mech Eng H 224:343–61
   PubMed Web of Science ®Google Scholar
• Ling L, Zhi-Yuan W, Jie L. (2011). The latest progress in the study of Keloid related genes. Med Recapitulate 17:3684–7
   Google Scholar
• Lutgendorf MA, Adriano EM, Taylor BJ. (2011). Prevention and management of keloid scars. Obstet Gynecol 118:351–6
   PubMed Web of Science ®Google Scholar
• Maurer BJ, Kang MH, Villablanca JG, et al. (2013). Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer 60:1801–8
   PubMed Web of Science ®Google Scholar
• Moda S, Cheung NK. (2010). Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 36:307–17
   PubMed Web of Science ®Google Scholar
• Ogawa R. (2010). The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg 125:557–68
   PubMed Web of Science ®Google Scholar
• Okuda T, Kawakami S, Higuchi Y, et al. (2009). Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. Int J Pharm 373:100–6
   PubMedGoogle Scholar
• Orienti I, Zuccari G, Carosio R, Montaldo PG. (2009). Improvement of aqueous solubility of fenretinide and other hydrophobic anti-tumor drugs by complexation with amphiphilic dextrins. Drug Deliv 16:389–98
   PubMed Web of Science ®Google Scholar
• Orienti I, Zuccari G, Falconi M, et al. (2012). Novel micelles based on amphiphilic branched PEG as carriers for fenretinide. Nanomedicine 8:880–90
   PubMed Web of Science ®Google Scholar
• Rapoport N, Gao Z, Kennedy A. (2007). Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 99:1095–106
   PubMed Web of Science ®Google Scholar
• Rapoport NY, Nam KH, Gao Z, Kennedy A. (2009). Application of ultrasound for targeted nanotherapy of malignant tumors. Acoust Phys 55:594–601
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Worden FP, Gadgeel SM, et al. (2009). Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 27:571–8
   PubMed Web of Science ®Google Scholar
• Shetlar MR, Shetlar CL, Hendricks L, Kischer CW. (1985). The use of athymic nude mice for the study of human keloids. Proc Soc Exp Biol Med 179:549–52
   PubMed Web of Science ®Google Scholar
• Shih B, Bayat A. (2010). Genetics of keloid scarring. Arch Dermatol Res 302:319–39
   PubMed Web of Science ®Google Scholar
• Simeone AM, Deng CX, Kelloff GJ, et al. (2005). N-(4-Hydroxyphenyl) retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carinogenesis 26:1000–7
   PubMed Web of Science ®Google Scholar
• Sogno I, Venè R, Ferrari N, et al. (2010). Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol 75:2–14
   PubMed Web of Science ®Google Scholar
• Trisliana Perdanasari A, Lazzeri D, Su W, et al. (2014). Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg 41:620–9
   PubMedGoogle Scholar
• Vaishampayan U, Heilbrun LK, Parchment RE, et al. (2005). Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs 23:179–85
   PubMed Web of Science ®Google Scholar
• Veronesi U, Mariani L, Decensi A, et al. (2006). Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065–71
   PubMed Web of Science ®Google Scholar
• Villablanca JG, London WB, Naranjo A, et al. (2011). Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res 17:6858–66
   PubMed Web of Science ®Google Scholar
• Ward M, Wu J, Chiu JF. (2000). Experimental study of the effects of Optison concentration on sonoporation in vitro. Ultrasound Med Biol 26:1169–75
   PubMed Web of Science ®Google Scholar
• Wei W, Zheng-Zhong B, Yong-Jie W, et al. (2004). Bioeffects of low-frequency ultrasonic gene delivery and safety on cell membrane permeability control. J Ultrasound Med 23:1569–82
   PubMed Web of Science ®Google Scholar
• Xu H, He L, Nie S, et al. (2009). Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release 140:61–8
   PubMed Web of Science ®Google Scholar
• Zhang H, Mi JQ, Fang H, et al. (2013). Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci U S A 110:5606–11
   PubMed Web of Science ®Google Scholar